3‐Oxotaraxer‐14‐en‐30‐al (1), a new taraxastane‐type triterpene, together with 14 known compounds, taraxerone (2), 3‐epiursolic acid (3), 2α,3β‐dihydroxyurs‐12‐en‐28‐oic acid (4), lupeol (5), betulinic acid (6), casticin (7), artemetin (8), luteolin (9), 4‐hydroxybenzoic acid (10), docosanoic acid (11), tetracosanoic acid (12), cerotic acid (13), β‐sitosterol (14), and β‐daucosterol (15), was isolated from the leaves and twigs of Vitex trifolia var. simplicifolia . Compounds 2–6 were found for the first time in this plant. Their structures were established by spectroscopic analysis, including 2D‐NMR techniques. Cytotoxic activities of compounds 3, and 5–10 were tested on the three cancer cell lines, PANC‐1, K562, and BxPC‐3. Results revealed that 7 exhibited cytotoxicity against PANC‐1, K562, and BxPC‐3, with IC50 values of 4.67, 0.72, and 4.01 μg/ml, respectively, whereas 8 was inactive against these cancer cell lines. The structureactivity relationship of compound 7 and 8 indicated that the 3′‐OH group in polymethoxyflavonoids is essential for antitumor activity.

A New Taraxastane-Type Triterpene from Vitex trifolia var. simplicifolia -[isolation, structure determination and cytotoxicity of the new taraxastane-type triterpene (I) and14 known compounds]. -(HUANG, M.-Y.; ZHONG, L.-J.; XIE, J.-M.; WANG, F.; ZHANG*, Y.-H.; Helv. Chim. Acta 96 (2013) 11, 2040-2045, http://dx.

No abstract

In this review, we summarized the distribution of the chemically investigated Oceanapia sponges, including the isolation and biological activities of their secondary metabolites, covering the literature from the first report in 1989 to July 2019. There have been 110 compounds reported during this period, including 59 alkaloids, 33 lipids, 14 sterols and 4 miscellaneous compounds. Besides their unique structures, they exhibited promising bioactivities ranging from insecticidal to antibacterial. Their complex structural characteristics and diverse biological properties have attracted a great deal of attention from chemists and pharmaceuticals seeking to perform their applications in the treatment of disease.

No abstract